The estimated Net Worth of Donna Hildebrand Kralowetz is at least 593 千$ dollars as of 8 July 2022. Ms Kralowetz owns over 1,149 units of Syneos Health Inc stock worth over 292,479$ and over the last 4 years she sold SYNH stock worth over 300,398$.
Ms has made over 6 trades of the Syneos Health Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 1,149 units of SYNH stock worth 84,061$ on 8 July 2022.
The largest trade she's ever made was selling 1,149 units of Syneos Health Inc stock on 8 July 2022 worth over 84,061$. On average, Ms trades about 203 units every 28 days since 2021. As of 8 July 2022 she still owns at least 6,805 units of Syneos Health Inc stock.
You can see the complete history of Ms Kralowetz stock trades at the bottom of the page.
Donna Hildebrand Kralowetz is the Sr. VP of Fin. & Principal Accounting Officer at Syneos Health Inc.
Ms Kralowetz is 50, she's been the Sr. VP of Fin. & Principal Accounting Officer of Syneos Health Inc since . There are 11 older and 7 younger executives at Syneos Health Inc. The oldest executive at Syneos Health Inc is William Klitgaard, 67, who is the Independent Director.
Donna's mailing address filed with the SEC is C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE, NC, 27560.
Over the last 7 years, insiders at Syneos Health Inc have traded over 16,280,601,287$ worth of Syneos Health Inc stock and bought 17,946 units worth 873,496$ . The most active insiders traders include Todd M Abbrecht、John L. Maldonado、Tom Allen. On average, Syneos Health Inc executives and independent directors trade stock every 14 days with the average trade being worth of 83,067,962$. The most recent stock trade was executed by Michael Lee Brooks on 28 July 2022, trading 1,502 units of SYNH stock currently worth 117,156$.
inc research/inventiv health has become syneos health, the only fully integrated end-to-end clinical and commercial solution organization. we are purpose-built for biopharmaceutical acceleration, creating better, smarter, faster ways to help clients navigate an increasingly complex marketplace. our new business addresses today’s market realities through clinical and commercial sharing expertise and data and insights to meet the needs of emerging and large global biopharmaceutical companies.
Syneos Health Inc executives and other stock owners filed with the SEC include: